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Summary
Background: The aim of this study was to investigate the effect of alpha lipoic acid
(-LA) on a porcine in-stent restenosis (ISR) model.
Methods: In protocol 1, porcine vascular smooth muscle cells (PVSMC) were stimu-
lated by granulocyte-colony stimulating factor (G-CSF) in the presence or absence of
-LA. MTT (3-[4,5-dimethylthiazole-2-yl] 2,5-diphenyl tetrazolium bromide) assay
and western blotting were used to determine the cell growth inhibitory rate and
anti-inﬂammatory effect associated with nuclear factor-b (NF-b) and extracellu-
lar signal-regulated kinase (ERK). In protocol 2, 28 days after balloon overdilation
injuries, 24 bare metal stents were placed in coronary artery of 12 pigs. The pigs
were randomly divided to receive control diet with or without -LA (100mg/kg). In
protocol 3, 8 control stents and 8 -LA coated stents were randomly implanted in
2 coronary arteries of 8 pigs and follow-up coronary angiogram and histopathologic
assessment were performed 4 weeks after stenting.
e proliferation of PVSMC was inhibited and protein expressionResults: Protocol 1. Th
of NF-b and ERK were attenuated by -LA pretreatment. Protocol 2. On histopatho-
logic analysis, the neointimal area (4.0± 1.0mm2 vs. 1.5± 0.7mm2, p < 0.001)
and histopathologic area of stenosis (66.7± 10.7% vs. 24.2± 9.7%, p < 0.001) were
reduced in the -LA feeding group compared to controls. Protocol 3. On histopatho-
logic analysis, the neointimal area (3.9± 0.8mm2 vs. 1.0± 0.4mm2, p < 0.001), and
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the histopathologic area of stenosis (67.1± 8.8% vs. 17.4± 10.0%, p < 0.001) were
reduced in the -LA coated stent group compared to the control stent group.
Conclusions: -LA feeding and -LA coated stents inhibit neointimal hyperplasia in
porcine ISR, possibly through inhibiting the activation of NF-b pathway and prolifer-
ation of PVSMC.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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heparin was administered intravenously as a bolus
prior to the procedure, the target coronary artery
was engaged using standard 7 F guide catheters© 2009 Japanese Colleg
reserved.
Introduction
Despite improvements in coronary interventions,
in-stent restenosis (ISR) remains a major problem
[1—3]. Drug-eluting stents (DES) have been consid-
ered the most successful tool in preventing ISR.
Unfortunately, it has been reported that DES may
result in delayed arterial healing and cause late
stent thrombosis when compared with bare metal
stent implantation [4,5]. In addition, the US Food
and Drug Administration has warned that DES may
be a cause of systemic and intrastent hypersen-
sitivity reactions, late thrombosis, and death [6].
Therefore, a new generation of DES to overcome
the inﬂammation, delayed endothelial healing, and
late stent thrombosis is needed.
-Lipoic acid (-LA) is a potent antioxi-
dant, and acts as a cofactor of key mito-
chondrial enzymes such as pyruvate dehydro-
genase and -ketoglutarate dehydrogenase [7].
-LA exists endogenously and improves diabetic-
induced endothelial dysfunction, probably due to
antioxidant effects and direct free-radical scav-
enging properties [8]. Moreover, -LA inhibits the
inﬂammatory pathway and prevents neointimal
hyperplasia after stenting in the carotid artery
[9,10].
The present study aimed to investigate whether
-LA feeding and -LA coated stents prevent ISR in
the porcine coronary artery restenosis model.
Methods
Protocol 1
We pretreated porcine aorta smooth muscle cells
(PASMCs; Modern Cell & Tissue Technologies, Seoul,
Korea) with -LA (100, 250, and 500mM) 24 h before
stimulation by granulocyte-colony stimulating fac-
tor (G-CSF) (100 ng/ml, CJ, Ichon, Korea). After 24 h
of G-CSF stimulation, we collected cell extracts
and performed immunoblotting for phospho-p65
(Cell Signaling, Danvers, MA, USA), extracellu-
lar signal-regulated kinases (ERK) (Cell Signaling),
phosphorylated ERK (Cell Signaling), signal trans-
a
i
i
bucers and activators of transcription (STAT)-3 (Cell
ignaling), phosphorylated STAT-3 (Cell Signaling),
nd -actin (Sigma, St Louis, MO, USA).
Next, we performed the proliferation rate
ssay. We pretreated -LA (100mM) with PASMCs
h before stimulation by G-CSF (100 ng/ml).
fter 48 h of G-CSF stimulation, MTT (3-[4,5-
imethylthiazole-2-yl] 2,5-diphenyl tetrazolium
romide, 5mg/ml in PBS, Sigma, Seoul, Korea) was
dded to cells, and they were incubated further
or 4 h at 37 ◦C. Supernatants were removed by
spiration, and then dimethyl sulfoxide (DMSO)
as added to solubilize the precipitated dyes.
bsorbance was measured at a wavelength of
70 nm.
nimal preparation
he animal study was approved by the Ethics Com-
ittee of Chonnam National University Medical
chool and Chonnam National University Hospital,
nd conformed to the Guide for the Care and Use
f Laboratory Animals published by the US National
nstitutes of Health (NIH Publication No. 85-23,
evised 1996). Study animals were female swine
eighing 25—35 kg. To prevent acute thrombosis
fter stenting, premedication with aspirin 100mg
nd clopidogrel 75mg per day was given for 7
ays before the procedure. On the procedure day,
igs were anesthetized with ketamine (20mg/kg
ntramuscularly) and xylazine (2mg/kg intramus-
ularly). They received intramuscular ketamine
very 30min and supplemental oxygen continuously
hrough oxygen mask. Subcutaneous 2% lidocaine at
he cut-down site was administered, left carotid
rtery was surgically exposed, and a 7 French
heath was inserted. Continuous hemodynamic and
urface electrocardiographic monitoring was main-
ained throughout the procedure. Then 5000 unitsnd control angiograms of both coronary arter-
es were performed using nonionic contrast agent
n two orthogonal views. The stent was deployed
y inﬂating the balloon and the resulting stent-
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o-artery ratio was 1.1:1. Coronary angiograms
ere obtained immediately after stent implanta-
ion. Then, all equipment was removed and the
arotid artery was ligated.
rotocol 2
alloon overdilatation injuries were performed in
he proximal left anterior descending artery and
roximal left circumﬂex by alternative manner for
2 pigs. Four weeks after the balloon overdilatation
njury, 24 bare metal stents (3.0mm× 17mm MAC;
MG, Raesfeld-Erle, Germany) were placed for 24
njured coronary arteries. The pigs were randomly
ivided to receive control diet (aspirin and clopi-
ogrel) with or without -LA (100mg/kg) during 4
eeks.
rotocol 3
he 8 bare metal (3.0mm× 17mm MAC) stents and
-LA coating (3.0mm× 17mm -LA coated MAC)
tents were implanted in the proximal left ante-
ior descending artery and proximal left circumﬂex
rtery by alternative manner for 8 pigs. All animals
eceived 100mg of aspirin and 75mg of clopidogrel
aily until death.
Four weeks after stenting, the animals under-
ent follow-up angiography in the same orthogonal
iews before death with 20ml of potassium chloride
ntracoronary injection. The hearts were removed,
nd the coronary arteries were pressure-perfusion
xed at 110 mmHg in 10% neutral buffered formalin
vernight. Arteries were step-sectioned, processed
outinely for light microscopy, and stained for his-
ological analysis.
-LA coating method
plasma polymerization reaction was performed
o attach amine radical to MAC stent (AMG) sur-
ace. Before the surface modiﬁcation, the MAC
tent is cleaned by conventional cleaning method
o remove macro-scale contaminants and with oxy-
en, argon, or argon and hydrogen plasma for
urther cleaning. A stent was ﬁxed in tubular reac-
or, which was made by pyrex glass tube, and then
he pressure was dropped to less than 5mTorr by
acuum pump.
For attachment of amine radical to stent sur-
ace, diaminocyclohexane monomer was drifted to
ubular reactor as constant dose (0.96 SCCM) and
lasma was generated using radiofrequency power
enerator. The power for polymerization of plasma
as 100W for 5min and then 60W for 15min. A
cm× 1 cm glass tube was boiled in 100 ◦C water
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or 5min and then taken out and allowed to dry
n an incubator. For the coating of -LA, the mod-
ﬁed stent is immersed in 2ml of -LA solution for
—80min at temperatures between 25 and 50 ◦C.
he carboxy radical of -LA was introduced to
mine radical attached to stent to achieve cova-
ent bond and improved attachment power between
tent and -LA. This reaction was performed for
h and then stent was taken out and allowed to
ry for more than 24 h. After the coating, the
tent was rinsed with deionized water for 1min to
emove weakly bound -LA. After grafting reaction,
he remaining solution was taken by UV—vis spec-
rophotometer (UV-2450, Shimadzu, Kyoto, Japan)
t 330 nm to determine the grafted amount. For the
elease kinetics of -LA from the stent, the stent
as placed in a glass vial and immersed in 100ml
f phosphate-buffered saline. The released amount
f -LA to the buffer solution was measured using
n absorbance test for ultraviolet at 278 nm [11].
istopathological analysis
or immunohistochemistry, the stent was removed
arefully from the coronary artery, and the
egments embedded in parafﬁn-blocks for immuno-
istochemical studies and methyl methacrylate.
ections were cut with the low speed dia-
ond wafer mounted to the Buehler Isomet saw
Buehler Ltd., Lake Bluff, IL, USA), leaving the
tent wires intact in the cross-sections to min-
mize potential artifacts from removal of stent
ires. Sections were obtained and stained with
ematoxylin—eosin stain for histological analysis.
he number of stained cells in the intima was quan-
iﬁed by counting 20 high-power ﬁelds using light
icroscopy. Immunohistochemical studies were
erformed using primary antibodies against STAT-3
Cell Signaling), phosphorylated STAT-3 (Cell Sig-
aling), Akt, phosphorylated Akt, and vascular
ndothelial growth factor (VEGF, Santa Cruz, Santa
ruz, CA, USA). Stain for proliferating cell nuclear
ntigen (PCNA, 1:2000, Dako, Glostrup, Denmark)
lso was done.
Measurements of the histopathologic sections
ere performed using a calibrated microscope,
igital video imaging system, and microcomputer
rogram (Visus 2000 Visual Image Analysis System,
MT Tech, San Diego, CA, USA). Borders were man-
ally traced for lumen area, area circumscribed by
he internal elastic lamina, and the innermost bor-
er of the external elastic lamina (external elastic
amina area). Morphometric analysis of neointimal
rea for a given vessel was calculated as the mea-
ured internal elastic lamina area minus lumen
rea.
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Arterial injury at each strut site was deter-
mined by the anatomic structures penetrated by
each strut. A numeric value was assigned, as pre-
viously described by Schwartz et al. [12]: 0 = no
injury; 1 = break in the internal elastic membrane;
2 = perforation of the media; 3 = perforation of the
external elastic membrane to the adventitia. The
average injury score for each segment was cal-
culated by dividing the sum of injury scores by
the total number of struts at the examined sec-
tion. Histopathologic stenosis was calculated as
100× (1− [lesion lumen area/lesion internal elastic
lamina area]).
With regard to the inﬂammatory score for each
individual strut, the grading is as follows: 0 = no
inﬂammatory cells surrounding the strut; 1 = light,
non-circumferential lymphohistiocytic inﬁltrate
surrounding strut; 2 = localized, moderate to dense
cellular aggregate surrounding the strut non-
circumferentially; and 3 = circumferential dense
lymphohistiocytic cell inﬁltration of the strut. The
inﬂammatory score for each cross-section was
v
m
w
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Figure 1 Semiquantitative immunoblotting of phospho-p65,
ERK), and phosphorylated signal transducers and activators of
cells. Densitometric analysis revealed increased protein ex
colony stimulating factor (G-CSF) stimulation, which was at
dose-dependent manner. The protein expression of nuclear f
pretreatment.S.Y. Lim et al.
alculated by dividing the sum of the individual
nﬂammatory scores by the total number of struts
t the examined section. The stent endothelial-
zation score was deﬁned as the extent of the
ircumference of the arterial lumen covered by
ndothelium and was scored from 1 to 3: 1, less
han 25%; 2, 25% to 75%; 3, more than 75%.
rugs and statistical analysis
rugs were purchased from Sigma Chemical Co. (St
ouis, MO, USA), unless stated otherwise. Statis-
ical analysis was performed with the aid of the
ommercially available software (SPSS Version 11,
PSS Inc., Chicago, IL, USA). The data are presented
s rates or mean value± SEM. Probability values are
wo-sided from the Student’s t-test for continuous
ariables and the Fisher exact test for categorical
ariables. To examine the correlations between the
easured histologic variables, regression analysis
as applied for each set of measured variables.
-Values <0.05 were considered signiﬁcant.
phosphorylated extracellular signal-regulated kinase (p-
transcription (p-STAT)3 in porcine aortic smooth muscle
pression of phospho-p65 and p-ERK after granulocyte-
tenuated by pretreatment with -lipoic acid (LA) in a
actor (NF)-b and p-ERK were also attenuated by -LA
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Figure 2 Columns show cell growth rate with or without pretreatment of -lipoic acid (LA) on granulocyte-colony
s h mu
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stimulating factor (G-CSF) induced porcine aortic smoot
-yl] 2,5-diphenyl tetrazolium bromide) assay. The grow
retreatment. *p < 0.05 compared with control cells, #p <
esults
ellular behavior and signaling molecules of
ASMCs
he protein expression of phospho-p65, phos-
horylated ERK, and phosphorylated STAT-3 were
ncreased on G-CSF stimulation in PASMCs, which
as attenuated by pretreatment with -LA dose
ependently. And the protein expression of
uclear factor (NF)-b and phosphorylated ERK
ere also attenuated by -LA pretreatment
Fig. 1).
To determine whether -LA prevents G-CSF-
nduced neointimal hyperplasia in PASMCs, cellular
rowth rate was determined by the MTT dye
ethod. It shows a gradual increased prolifera-
ion of PASMCs treated with G-CSF compared to
he control, while it was attenuated by pretreat-
2
T
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Table 1 Quantitative coronary angiographic ﬁndings of p
study.
Control grou
Baseline (2)
Proximal diameter 3.1 ± 0.6
Distal diameter 2.7 ± 0.4
Reference diameter 2.9 ± 1.1
Post-stenting diameter 3.2 ± 0.9
4 weeks after stenting (mm)
Proximal diameter 3.1 ± 0.7
Distal diameter 2.8 ± 0.2
Target reference diameter 2.9 ± 0.1
Minimal luminal diameter 1.7 ± 0.3
Values are expressed as mean± SEM.
* p < 0.05, when compared with control group.scle cell proliferation by MTT (3-[4,5-dimethylthiazole-
ate was accelerated by G-CSF and attenuated by -LA
compared with G-CSF stimulated cells.
ent with -LA at 48 h after G-CSF stimulation
Fig. 2).
ffects of alpha-LA feeding on ISR
ortality for this study was zero. There was no sig-
iﬁcant difference in stent-to-artery ratio between
wo groups. On histopathologic analysis, injury
core, internal elastic lamina areas were not signif-
cantly different between the two groups (Table 1).
he neointimal area was 4.0± 1.0mm2 in the con-
rol group and 1.5± 0.7mm2 in the -LA feeding
roup (p < 0.001), and the histopathologic area of
tenosis was 66.7± 10.7% in the control group and
4.2± 9.7% in the -LA feeding group (p < 0.001,
able 2, Fig. 3A and B). The inﬂammatory score
as 2.8± 1.5 in the control group and 1.3± 0.4 in
he -LA feeding group (p < 0.05, Table 2, Fig. 3C
nd D). The endothelialization score showed no
orcine coronary arteries in -lipoic acid (LA) feeding
p (n = 12) -LA feeding group (n = 12)
3.0 ± 1.1
2.6 ± 0.9
2.9 ± 0.1
3.2 ± 0.7
3.1 ± 0.7
2.6 ± 0.2
2.8 ± 0.2
3.0 ± 0.2*
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Table 2 Histopathologic assessment of porcine coronary arteries in -lipoic acid (LA) feeding study.
Control group (n = 12) -LA feeding group (n = 12)
Injury score 1.7 ± 0.7 1.3 ± 0.5
Lumen area (mm2) 1.9 ± 0.4 4.6 ± 0.7*
IEL area (mm2) 5.9 ± 0.8 6.1 ± 0.7
Neointima area (mm2) 4.0 ± 1.0 1.5 ± 0.7*
Area stenosis (%) 66.7 ± 10.7 24.2 ± 9.7*
Inﬂammation score 2.8 ± 1.5 1.3 ± 0.4*
Endothelialization score 2.9 ± 0.8 2.9 ± 0.9
na.
c
a
a
oValues are expressed as mean± SEM. IEL, internal elastic lami
* p < 0.05, when compared with control group.
signiﬁcant difference between the two groups
(Table 2).Effects of alpha-LA coated stent on ISR
The median thickness of coating was 1m and the
amount of -LA coating on the surface of the stent
was 200g/stent. The grafted amount of ALA was
m
r
d
w
Figure 3 Methyl methacrylate (A and B) and hematoxylin an
study. In-stent neointimal area was smaller in the -LA feed
group; (B) -LA feeding group. Magniﬁcation: 10×. -LA fe
compared with control group. (C) Control group; (D) -LA feealculated from the UV standard calibration curve
nd the grafted amount onto a stent surface was
bout 200g. The -LA coating on the surface
f the stent was conﬁrmed by scanning electron
icroscopy. Release kinetics demonstrated stable
elease of -LA from the stent surface over 35
ays [12]. The mortality rate was also zero. There
as no signiﬁcant difference in stent-to-artery ratio
d eosin (C and D) stain in the -lipoic acid (LA) feeding
ing group compared with the control group. (A) Control
eding group shows lower inﬂammatory cell inﬁltration
ding group. Magniﬁcation: 200×.
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Table 3 Quantitative coronary angiographic ﬁndings of porcine coronary arteries in -lipoic acid (LA) coated stent
study.
Control stent group (n = 8) -LA coated stent group (n = 8)
Baseline (2)
Proximal diameter 3.1 ± 00.6 3.0 ± 0.8
Distal diameter 2.7 ± 0.7 2.7 ± 0.9
Reference diameter 2.9 ± 0.2 2.8 ± 0.7
Post-stenting diameter 3.2 ± 0.9 3.1 ± 0.7
4 weeks after stenting (mm)
Proximal diameter 3.1 ± 0.7 3.0 ± 0.9
Distal diameter 2.8 ± 0.2 2.6 ± 0.2
Target reference diameter 2.9 ± 00.1 2.9 ± 0.2
Minimal luminal diameter 1.6 ± 0.4 3.1 ± 0.2*
Values are expressed as mean± SEM.
* p < 0.05, when compared with control group.
Table 4 Histopathologic assessment of porcine coronary arteries in -lipoic acid (LA) coated stent study.
Control stent group (n = 8) -LA coated stent group (n = 8)
Injury score 1.7 ± 0.7 1.3 ± 0.5
Lumen area (mm2) 1.9 ± 0.4 4.9 ± 1.2*
IEL area (mm2) 5.8 ± 0.7 5.9 ± 0.9
Neointima area (mm2) 3.9 ± 0.8 1.0 ± 0.4*
Area stenosis (%) 67.1 ± 8.8 17.4 ± 10.0*
Inﬂammation score 2.4 ± 0.7 1.1 ± 0.6*
Endothelialization score 2.9 ± 0.8 2.9 ± 0.7
na.
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aValues are expressed as mean± SEM. IEL, internal elastic lami
* p < 0.05, when compared with control group.
etween the two groups. The injury score and
nternal elastic lamina area were not signiﬁcantly
ifferent between the two groups (Table 3). The
eointimal area was 3.9± 0.8mm2 in the control
tent group and 1.0± 0.4mm2 in the -LA coated
tent group (p < 0.001), and the histopathologic
rea of stenosis was 67.1± 8.8% in the control stent
roup and 17.4± 10.0% in the -LA coated stent
roup (p < 0.001, Table 4, Fig. 4A and B). The inﬂam-
atory score was 2.4± 0.7 in the control group and
.1± 0.6 in the -LA coated stent group (p < 0.05,
able 4, Fig. 4C and D). The endothelialization score
howed no signiﬁcant difference between the two
roups (Table 4).
mmunohistochemical analysis
ig. 5 shows the immunohistochemical staining for
-Akt (Fig. 5A and B) and VEGF (Fig. 5C and D). The
tent-based -LA delivery inhibits p-Akt and VEGF
xpression in PASMCs effectively. Fig. 6 shows the
mmunohistochemical staining for p-STAT-3 (Fig. 6A
nd B) and PCNA (Fig. 6C and D). The stent-based
-LA delivery inhibits p-STAT-3 expression and cell
roliferation effectively.
T
b
a
piscussion
his study demonstrates that both oral adminis-
ration of -LA and -LA coated stents inhibit
eointimal formation in the porcine coronary
estenosis model. The profound reduction in neoin-
imal formation with oral -LA and -LA coated
tent is associated with an inhibition of activation
f NF-b, ERK, STAT-3, and proliferation of vascu-
ar smooth muscle cells. Our ﬁndings document the
easibility of oral administration of -LA and -LA
oated stent, and the efﬁcacy data support the
otion that stent-based -LA delivery is a promising
pproach for the prevention of restenosis.
ISR due to neointimal hyperplasia remains the
ajor limitation of coronary stent implantation.
he development of neointimal hyperplasia plays
n important role in the mechanism of resteno-
is [13]. Because of the role of inﬂammation in
estenosis, the inﬂammatory cells seemed to be
n optimal target in the ﬁght against restenosis.
he pathological process of ISR is characterized
y an inﬂammatory healing response after stretch
nd damage of the vessel wall [14,15]. Initially,
latelets are activated and attach around the stent
382 S.Y. Lim et al.
Figure 4 Methyl methacrylate (A and B) and hematoxylin and eosin (C and D) stain in the -lipoic acid (LA) coated
stent study. In-stent neointimal area was smaller in the -LA coated stent group compared with the control group. (A)
n: 10
grou
e
w
e
p
t
v
e
g
r
i
p
m
t
t
E
g
wControl group; (B) -LA coating stent group. Magniﬁcatio
cell inﬁltration compared with control group. (C) Control
struts followed by adhesion of inﬂammatory cells.
Cytokines and growth factors are released, leading
to migration and proliferation of vascular smooth
muscle cell [16].
Based on observations that ISR is a consequence
of inﬂammation, smooth muscle cell prolifera-
tion, and migration, several immunosuppressive
and antiproliferative therapies have been investi-
gated to inhibit these processes [17—19]. Recent
successes in early clinical trials with DES using
antiproliferative agents such as sirolimus and pacli-
taxel have been quite promising [20—22]. Sirolimus
inhibits smooth muscle cell proliferation by block-
ing the cell cycle in the G1 (growth) to S (DNA
synthesis) phase, thus preventing cell replication.
Paclitaxel works by binding to polymerized tubu-
lin, thereby stabilizing it against disassembly, thus
inhibiting cell mitosis (M-phase of the cell cycle).
However, current DES result in delayed arterial
healing and may cause late stent thrombosis and
even cause death, and many clinical cases have
been reported [4—6].
i
a
s×. The -LA feeding group showed lower inﬂammatory
p; (D) -LA coated stent group. Magniﬁcation: 200×.
-LA has been used as therapy for many dis-
ases, especially diabetes. -LA supplementation
as reported to increase unbound lipoic acid lev-
ls, which can reduce oxidative stress and act as a
otent antioxidant [23]. -LA is readily converted
o its reduced form dihydrolipoic acid (DHLA) in
arious tissues, which increases intracellular lev-
ls of coenzyme NADPH, and NADH via increased
lutathione availability. Both -LA and DHLA have
ecently gained some recognition as useful biolog-
cal antioxidants. They inﬂuence a number of cell
rocesses including direct radical scavenging, and
odulating transcription factor activity, especially
hat of NF-b [24,25]. The present in vivo data show
he protein expression of NF-b and phosphorylated
RK was attenuated by -LA pretreatment and sug-
ests that -LA has anti-inﬂammatory effects as
ell as a previous known antioxidant effect.
The cellular proliferation induced by G-CSF was
nhibited by -LA pretreatment in MTT assay. In
ddition, in porcine experiment, staining for PCNA
howed a lower ratio of PCNA positive cells in the -
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Figure 5 Immunohistochemical staining for phosphorylated Akt and vascular endothelial growth factor (VEGF). (A)
a lipoi
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Snd (C) Control stent (bare metal stent); (B) and (D) -
mmunolabeling of p-Akt effectively after 28 days of sten
A coated stent group. These data suggest that -LA
ay attenuate cell proliferation. Moreover, a sig-
iﬁcant reduction in stent-associated inﬂammation
nd neointimal hyperplasia was observed at 28 days
or both administration of oral -LA and stent-based
ocal delivery of -LA and suggests that both -LA
nd its reduced form, DHLA, have similar antipro-
iferatory and anti-inﬂammatory effects on vascular
mooth muscle cells.
In our data, endothelialization score showed no
igniﬁcant difference after -LA treatment com-
ared with bare metal stent. We thought that is
he difference between this and preexisting DES,
uch as sirolimus- or paclitaxel-eluting stents. If the
ame result could be reproduced in human stud-
es, the -LA coating stent may be an ideal stent
hat inhibits neointimal proliferation effectively
nd does not interfere with re-endothelialization.
We used antibodies for STAT-3 and ERK in westernlotting and Akt, VEGF, and STAT-3 for immuno-
istochemical staining. There have been several
eports suggesting that STAT-3 phosphorylation pro-
otes smooth muscle cell growth [26]. VEGF plays
I
i
a
s
oc acid (LA) coated stent. -LA coated stent attenuated
. Magniﬁcation: 200×.
n important role in neointimal development in ves-
el wall injury [27,28]. In our porcine model, VEGF
as expressed at high levels in the neointima of the
are metal stent group. Activation of the Akt path-
ay triggered by mechanical stretch may also be
contributory factor to ISR formation [29]. Acti-
ation of ERK and c-Jun N-terminal kinase (JNK)
riggers smooth muscle cell proliferation, leading
o neointimal formation [30,31].
Prevention of ISR appears to require such a mul-
ipronged attack to block all the processes. In our
tudy, -LA blocked multiple cytokines such as Akt,
RK, VEGF, and STAT-3 and inhibited the prolifera-
ion of vascular smooth muscle cells.
tudy limitationst remains to be established whether our ﬁnd-
ngs in normal non-atherosclerotic porcine coronary
rteries stimulated with oversized balloons and
tents for neointimal proliferation could be extrap-
lated to human clinical scenarios with preexisting
384 S.Y. Lim et al.
Figure 6 Immunohistochemical staining for phosphorylated signal transducers and activators of transcription (p-STAT)-
C) C
olab
M
R
F
R3 and proliferating cell nuclear antigen (PCNA). (A) and (
(LA) coated stent. -LA coated stent attenuated immun
stenting. Magniﬁcation: 200×.
atherosclerosis. Second, the observed efﬁcacy at
28 days may not be sustained after the drug con-
centration wanes to a subtherapeutic level and the
dose—response effects for this -LA coated stent
are incompletely characterized.
Conclusions
This is the ﬁrst experimental study to demonstrate
that administration of oral -LA and -LA coated
stents are feasible and effectively reduce in-stent
neointimal formation. Stent-based local delivery of
-LA profoundly suppresses neointimal hyperpla-
sia in the porcine ISR model by inhibition of ERK,
STAT-3, and proliferation of vascular smooth muscle
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